Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Ordinary Shares, Euro 0.12 par value per share
-
Shares outstanding
-
62,254,300
-
Total 13F shares
-
40,745,703
-
Share change
-
+11,689,810
-
Total reported value
-
$1,142,917,292
-
Price per share
-
$28.05
-
Number of holders
-
36
-
Value change
-
+$328,263,856
-
Number of buys
-
30
-
Number of sells
-
6
Institutional Holders of Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS) as of Q4 2023
As of 31 Dec 2023,
Pharvaris N.V. - Ordinary Shares, Euro 0.12 par value per share (PHVS) was held by
36 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
40,745,703 shares.
The largest 10 holders included
GENERAL ATLANTIC, L.P., FMR LLC, venBio Partners LLC, Foresite Capital Management IV, LLC, Bain Capital Life Sciences Investors, LLC, VIKING GLOBAL INVESTORS LP, VR Adviser, LLC, Cormorant Asset Management, LP, Novo Holdings A/S, and EcoR1 Capital, LLC.
This page lists
36
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.